Dr Stiller is Chief, Section of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Bridgeport Hospital, Bridgeport, Connecticut, and Clinical Professor of Obstetrics and Gynecology, Yale University School of Medicine.
Dr Hicks is Resident in the Department of Obstetrics and Gynecology, Bridgeport Hospital, Bridgeport, Connecticut.
Dr Saul is Chief, Section of Infectious Disease, Department of Internal Medicine, Bridgeport Hospital, Bridgeport, Connecticut, and Clinical Instructor of Medicine, Yale University School of Medicine.
Ob/gyns have witnessed how development of antibiotic resistance has affected disease management in our specialty. Increased resistance of Neisseria gonorrhea (N gonorrhea) to penicillins and quinolones, emergence of methicillin-resistant staphylococcus aureus (MRSA) and resistance of Group B Streptococcus to erythromycin and clindamycin have led us to modify our antibiotic treatment regimens. Whether antibiotics are appropriately or inappropriately prescribed, they can lead to loss of effectiveness by allowing only organisms with resistance to survive and multiply in a process similar to natural selection. Alternatively, organisms can share genetic information through plasmids, which are small segments of DNA that can code for production of resistance factors.
Urinary tract infections (UTIs) complicate 3% to 10% of pregnancies and are among the most common reasons for antibiotic use in obstetrics.1 Clinically relevant disease may include lower urinary tract conditions such as asymptomatic bacteriuria and acute cystitis or upper tract urinary infections such as pyelonephritis. In pregnancy, these infections are most frequently caused by the Enterobacteriaceae group of organisms, which include the gram negative rods, Escherichia coli (E coli) (82.5%), Klebsiella pneumoniae (K pneumoniae) (7.6%), Proteus mirabilis (4.9%), and Enterobacter species (5.7%). Gram positive organisms such as Streptococcus species (21.4%), Staphylococcus species (6.5%), and Enterococcus species (5.7%) also cause infections, although frequencies of specific organisms vary among case series.2
None of the authors has a conflict of interest to report in respect to the content of this article.
- Glaser A, Schaeffer A. Urinary Tract Infection and Bacteriuria in Pregnancy Urol Clin N Am 2015;42:547-60
- Wing D, Fassett M, Getahun D. Acute Pyelonephritis in Pregnancy; an 18-year retrospective analysis. Am J Obstet Gynecol 2014:210:219e1-6.
- Adler A, Katz D, Marchaim D. The Continuing Plague of Extended-spectrum b-lactamase–producing Enterobacteriaceae Infections. Infect Dis Clin N Am 2016;30: 347–375
- Doi Y, Park Y, Rivera J, Adams-Haduch J, Hingwe A, Sordillo E, Lewis J, Howard W, Johnson L, Polsky B, Jorgensen J, Richte S, Shutt K, Paterson D. Community-Associated Extended-Spectrum β-Lactamase–Producing Escherichia coli Infection in the United States. Clin Infect Dis 2013;56:641–8.
- Pelig A, Hooper D. Hospital-Acquired Infections due to Gram-Negative Bacteria. NEJM 2010;362:1804-13
- Lob S, Nicolle L, Hoban D, Kazmierczak K, Badal R, Sahm D. Susceptibility patterns and ESBL rates of Escherichia from urinary tract infections in Canada and the United States, SMART 2010-2014. Diagn Microbiol Infect Dis 2016; 85: 459-65
- Eppes C, Clark S. Extended-spectrum b-lactamase infections during pregnancy: a growing threat. Am J Obstet Gynecol 2015;213:650-652.
- The Center for Disease Control. Antimicrobial/Antibiotic Resistance: Biggest Threats. http://www.cdc.gov/drugresistance/biggest_threats.html. Accessed July 19, 2016
- Vazquez J, Abalos E. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database of Systematic Reviews. 2011, Issue 1. Art. No.: CD002256.
- Michalopoulos A, Livaditis I, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011;15: e732–e739.
- Estebanez A, Pascual R, Gil V, Ortiz F, Santibáñez M, Pérez Barba C. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis 2009;28:1457-1464.
- Khawaja A, Khan F, Dar T, Bhat A, Wani M, Wazir B. Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study. Cent European J Urol. 2015;68:371-375.
- Falagas M, Kastoris A, Kapaskelis A, Karageorgopoulos D. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing Enterobacteriaceae infections: a systemic review. Lancet Infect Dis 2010;10:43-50.
- Vardakas K, Legakis N, Triarides N, Falgas M. Susceptibility of contemporary isolates to fosfomycin; a systemic review of the literature. Int J Antimicrob Agents 2016; 47:269-285.
- Papp-Wallace K, Endimiani A, Taracilia M, Bonomo R. Carbapenems: Past, Present, and Future Antimicrob Agents Chemother 2011;55:4943-4960.
- Zhanel G, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban D, Noreddin A, Karlowsky J. Comparative review of the carbapenems. Drugs. 2007;67:1027-1052.
- Veve M, Wagner J, Kenney R, Grunwald J, Davis S. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Internat J Antimicrob Agents 2016; 48: 56–60.
- Doi Y, Paterson D. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med. 2015;36:74-84.
- Khatri A, Murphy N, Wiest P, Osborn M, Garber K, Hecker M, Hurless K, Rudin S, Jacobs M, Kalayjian R, Salata R, Duin D, Perez F, Bonomo R. Community –Acquired Pyelonephritis in Pregnancy Caused by KPC Producing Klebsiella Pneumoniae. Antimicrob Agents Chemother 2015; 59:4375-4378.
- Mawal Y, Critchley I, Riccobene T, Talley A. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Expert Rev Clin Pharmacol 2015:8:691-707.
- Sharma R, Park T, Moy S. Caftazadime-Avibactam: A novel cephalosporin/beta-lactamase Inhibitor combination for the treatment of resistant gram negative organisms. Clin Therap 2016;38:431-444.
- Giamarellou H, Poulakou G. Multidrug-Resistant Gram-Negative Infections. What are the Treatment Options? Drugs 2009; 69 (14): 1879-1901